Compass Therapeutics received FDA Fast Track Designation for CTX-009, progressing enrollment in studies
From GlobeNewswire: 2024-05-13 08:00:00 Compass Therapeutics received FDA Fast Track Designation for CTX-009 in combination with paclitaxel for biliary tract
